|
Newsbrief:
MAPS-Sponsored
Ecstasy
Research
Wins
Final
FDA
Approval
9/26/03
The Multidisciplinary Association
for Psychedelic Studies (MAPS) announced Tuesday that its groundbreaking
study on the therapeutic use of MDMA (ecstasy) in treating Post Traumatic
Stress Disorder has conquered the penultimate government hurdle.
The Institutional Review Board reviewing the proposed research granted
final approval Tuesday, after nearly two years of allowing it to languish.
The Institutional Review
Board decision is required under Food and Drug Administration (FDA) guidelines.
The FDA approved the study in November 2001. MAPS noted that it took
eight separate applications before various IRBs before succeeding this
week.
Now, the proposed study lacks
only the issuance of a DEA Schedule I license for researcher Dr. Michael
Mithoefer. MAPS applied for that license 15 months ago. "We
hope to receive a license somewhat quickly now that IRB approval has been
obtained, but you can never tell with DEA," the group noted. Once
that license has been granted, the research can begin.
Researchers in the 1980s
began research into MDMA's therapeutic effects on a number of disorders,
but that research was squelched when MDMA was reclassified as a Schedule
I substance in 1986 after partiers in Texas were observed having way too
much fun with it. MAPS has been instrumental in attempting to get
research into the drug's therapeutic uses going in, and has even crafted
a "5-year Clinical Plan to make MDMA into a prescription medicine for the
treatment of post-traumatic stress disorder."
For more information, visit
the MDMA research pages at MAPS, http://www.maps.org/research/mdma/.
-- END --
|
Issue #304, 9/26/03
Editorial:
Patients vs. Prosecutors |
Pain Doctor Arrests
Provoke Backlash -- Group Urges FDA to Stop Cooperating With Justice Department |
Cheryl Miller
Memorial Project Does DC |
Hawaii Meth Mania:
Drug Summit, Media Push Target "Ice" |
Playing It Smart:
Sensible Seattle and the Winning of I-75 |
Newsbrief:
Dr. Hurwitz Indicted, Jailed in Campaign Against Pain Doctors |
Newsbrief:
MAPS-Sponsored Ecstasy Research Wins Final FDA Approval |
Newsbrief:
Rio de Janeiro Jails Stuffed With Drug Offenders |
Newsbrief:
UN Warns Stimulants "Public Enemy Number One," Cites Flawed Science, Attacks
"Liberalization" |
Newsbrief:
This Week's Corrupt Cops Story |
Newsbrief:
Cannabis Tolerance Showing Up in India |
Newsbrief:
Canadian Government to Appeal BC Marijuana Legalization Ruling |
Newsbrief:
Drug War Sparking Death Squad Killings Again in Philippines |
Newsbrief:
Ashcroft Says No Plea Bargains in Latest Bid to Send America to Prison
Forever |
Newsbrief:
Mandatory Minimum Sentences Unfair, Says Supreme Court Justice |
This Week
in History |
Current Action
Alerts: Medical Marijuana, Plan Colombia, HEA, Ashcroft's Attack
on Judicial Discretion |
Perry Fund
Accepting Applications for 2003-2004 and 2004-2005 School Years, Providing
Scholarships for Students Losing Aid Because of Drug Convictions |
Errata:
Last Week's Corrupt Cops Story |
The Reformer's
Calendar
|
This issue -- main page
This issue -- single-file printer version
Drug War Chronicle -- main page
Chronicle archives
|
PERMISSION to reprint or
redistribute any or all of the contents of Drug War Chronicle (formerly The Week Online with DRCNet is hereby
granted. We ask that any use of these materials include proper credit and,
where appropriate, a link to one or more of our web sites. If your
publication customarily pays for publication, DRCNet requests checks
payable to the organization. If your publication does not pay for
materials, you are free to use the materials gratis. In all cases, we
request notification for our records, including physical copies where
material has appeared in print. Contact: StoptheDrugWar.org: the Drug Reform Coordination Network,
P.O. Box 18402, Washington, DC 20036, (202) 293-8340 (voice), (202)
293-8344 (fax), e-mail [email protected]. Thank
you.
Articles of a purely
educational nature in Drug War Chronicle appear courtesy of the DRCNet
Foundation, unless otherwise noted.
|
